Loading stock data…
VERA
$31.71-0.10 (-0.31%)
Market OpenUpdated 3:00 PM EDT
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vera Therapeutics, Inc. in the Healthcare sector is trading at $31.71. Wall Street consensus targets $78.00 (14 analysts), implying a +146.0% move over the next 12 months. The stock is currently 43% below its 52-week high of $56.05, remaining 13.9% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +146.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$125.13M↓ | -$94.21M↓ | -$83.93M↓ | -$80.14M↓ | -$57.19M |
| Net Income | -$121.03M↓ | -$91.10M↓ | -$80.29M↓ | -$76.53M↓ | -$51.69M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion pr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-73.84%
Volume
Today's trading volume
363,562
Recent News
Will FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy Narrative
Earlier in June 2026, Vera Therapeutics reported it had reached agreement with the FDA on an accelerated eGFR analysis plan for the ORIGIN 3 trial of atacicept in adults with IgA nephropathy, aiming to support a supplemental Biologics License Application for full approval later in 2026. This regulatory alignment, underpinned by supportive Phase 2b eGFR data and recent multi-stakeholder input from a National Kidney Foundation workshop, sharpens visibility on atacicept’s potential path toward...
A Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial Analysis
Vera Therapeutics (VERA) stock is in focus after the company reached agreement with the FDA on an earlier eGFR analysis for its ORIGIN 3 trial of atacicept in IgA nephropathy. See our latest analysis for Vera Therapeutics. At a share price of US$32.29, Vera Therapeutics has seen its share price fall 19.8% over the past 90 days and 33.6% year to date, even as its 1 year total shareholder return of 45.5% and very large 3 year total shareholder return of about 2.6x point to momentum that has so...
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% an
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment
The biotech moves a step closer to full approval in IgAN as regulators agree to an accelerated timeline for key kidney function data review.
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.